Altavant Sciences GmbH
8Patents
8Active
8Granted
48Portfolio score
Filing activity: Nov 14, 2019 → Jul 18, 2022
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11203597B2 | Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing | Chemistry; Metallurgy | 1 | Active |
| US11576915B2 | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing | Human Necessities | 1 | Active |
| US11091763B2 | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors | Chemistry; Metallurgy | 1 | Active |
| US11607413B2 | Dosage regime and method for treating pulmonary arterial hypertension | Human Necessities | 1 | Active |
| US11413287B2 | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension | Human Necessities | 1 | Active |
| US11708365B2 | Processes for preparing TPH1 inhibitors | Emerging Cross-Sectional Technologies | 0 | Active |
| US11759462B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | Emerging Cross-Sectional Technologies | 0 | Active |
| US11911382B2 | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.